C1 - Nucleotide signalling in the heart

Question 1 of 1

  Time Left


0
51211
0
120
block

Nucleotide Signalling Experiments (1)

Match the text (click and drag)   

(0/0)




Match the text

Zacollo & Pozzan aims

Zacollo & Pozzan methods

Zacollo & Pozzan results

Lygren aims

Lygren methods

Lygren results

Mongillo aims

Mongillo methods

Mongillo results

Beca aims

Beca methods

Beca results

Click and drag

cAMP localised to microdomains @ T-tubules/SR membrane, ~1um. IBMX disrupts localisation of signalling.

PDE3A predominant enzyme, associates with the AKAP18d complex described by Lygren et al

SR depletion with SERCA inhibitor BHQ, Ca added to EC compartment. siRNA AKAP18d knockdown -> attenuates reuptake.

Neonatal rat cardiac myocytes. [cAMP] assessed by FRET from cyan->yellow GFP. effects of PDE inhibitor IBMX also assessed.

Studied the spatio-temporal changes in cAMP following B-AR activation

Studied roles of PDE3&4 in cAMP signalling at rest and after B-AR activation.

AKAP18d facilitates formation of signalling complex, disruption prevents PLN from being phosphorylated & dissociating from SERCA.

PDE4 inhibitor disrupted cAMP signalling at rest & after B-AR activation significantly more than did PDE3 inhibition.

[cAMP] measured w/ FRET (as above), PDE3 & PDE4 inhibitors applied at rest and after iso.

Investigated the roles of PDE3A&B in regulating basal contractility and SR Ca content.

Determine the effects of AKAP18d siRNA knockdown on SR Ca uptake/release.

Isolated lagendorff hearts, contractility & relaxation enhanced in PDE3A KO mice but not PDE4A KO mice. Co-immunoprecipitation showed that PDE3A colocalises with SERCA2, PLN, AKAP18d, & PP2A


51212
0
120
none
51191
0
120
none